Neoadjuvant immunotherapy for non-small cell lung cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Immunotherapy with immune checkpoint inhibitors is an essential component of modern drug therapy for advanced non-small cell lung cancer. Phase 1-2 clinical trials of neoadjuvant immunotherapy (NAIT) of early-stage lung cancer are showing promising results. Phase 3 multicenter prospective studies to confirm the possibility of increasing overall survival in patients receiving preoperative immunotherapy are currently underway. The search for predictive biomarkers and the study of optimal methods for assessing the effectiveness of NAIT continue.

Full Text

Restricted Access

About the authors

Anna I. Semenova

N.N. Petrov National Medical Research Center of Oncology

Email: mirannia@yandex.ru
Cand. Sci. (Med.), Senior Researcher at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, Oncologist at the Department of Chemotherapy and Innovative Technologies, Associate Professor at the Department Saint Petersburg, Russia

S. A Protsenko

N.N. Petrov National Medical Research Center of Oncology

Saint Petersburg, Russia

G. M Teletaeva

N.N. Petrov National Medical Research Center of Oncology

Saint Petersburg, Russia

D. Kh Latipova

N.N. Petrov National Medical Research Center of Oncology

Saint Petersburg, Russia

A. V Novik

N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University

Saint Petersburg, Russia

References

  1. Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. doi: 10.3322/caac.21492.
  2. Yotsukura M., Nakagawa K., Suzuki K., et al. Recent advanced and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer. Jap J Clin Oncol. 2021;51(1):28-36. Doi: 10.1093/ jjco/hyaa187.
  3. Topalian S.I., Taube J.M., Pardoll D.M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;40:1-12.
  4. Broderick S.R. Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer. Thorac Surg Clin. 2020;215-20. Doi: 10.1016/j. thorsurg.2020.01.001.
  5. Forde P.M., Chaft J.E., Smith K.N., et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976-86. doi: 10.1056/NEJMoa1716078.
  6. Kwiatkowski D.J., Chaft J.E., Be J. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3). J Clin Oncol. 2019;37:Abstr 8503.
  7. Ready N., Tong B., Clarke J., et al. Neoadjuvant pembrolizumab in early stage non-small cell lung cancer (NSCLC): Toxicity, efficacy, and surgical outcomes. J Thorac Oncol. 2019;14:S745.
  8. Provencio M., Nadai F., Insa A., et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small cell lung cancer (NADIM): an open-label, multicenter, single-arm, phase 2 trial. Lancet. Oncol. 2020;21:1413-22. doi: 10.1016/S1470-2045(20)30453-8.
  9. Cascone T., Nassib W., Weissferdt A., et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. J Clin Oncol. 2019;37:Abstr. 8504.
  10. Tao X., Li N, Wu N., et al. The efficiency of (18) F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47:1209-19. doi: 10.1007/s00259-020-04711-3.
  11. Travis W.D., Dacic S., Wistuba I., et al. IASLC Multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol. 2020;15:709-40. Doi: 10.1016/j. jtho.2020.01.005.
  12. Chae Y.K., Oh M.S. Detection of minimal residual disease using ctDNA in lung cancer: biomarker sources and therapeutic applications. Cancer Chemother Pharmacol. 2018;82:171-83. doi: 10.1007/s00280-018-3586-8.
  13. Liang W., Cai K., Chen C., et al. Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2020;9(6):2696-715. doi: 10.21037/tlcr-2020-63.
  14. Uprety D., Mandrekar S.J., Wigle D., et al. Neoadjuvant immunotherapy for NSCLC: Current concepts and future approaches. J Thorac Oncol. 2020;15:1281-97. Doi: 10.1016/j. jtho.2020.05.020.
  15. Provencio M., Nadal E., Insa A., et al. Neoadjuvant chemo-immunotherapy for the treatment of STAGE IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study Final data of patients who underwent surgical assessment. J Clin Oncol. 2019;37: abstr 8509.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies